Skip to main content

Drugs

Ausgabe 2/2024

Inhalt (11 Artikel)

Review Article

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

Camille Allard, Daniela Cota, Carmelo Quarta

Open Access Review Article

Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature

Willemijn A. M. Schonck, Erik S. G. Stroes, G. Kees Hovingh, Laurens F. Reeskamp

Original Research Article

Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry

Jonathan Schimmel, Lindsey Claire Epperson, Kim Aldy, Paul Wax, Jeffrey Brent, Jennie Buchanan, Michael Levine, Keith Burkhart

Open Access Adis Drug Evaluation

Lumasiran: A Review in Primary Hyperoxaluria Type 1

Connie Kang

Adis Drug Evaluation

Tirzepatide: A Review in Type 2 Diabetes

Nicole L. France, Yahiya Y. Syed

AdisInsight Report

Repotrectinib: First Approval

Sohita Dhillon

AdisInsight Report

Etrasimod: First Approval

Matt Shirley

Open Access Correction

Correction to: Nedosiran: First Approval

Yahiya Y. Syed

Aktuelle Ausgaben